Month: June 2025
-
Apple-funded astroturfers caught LYING about organization’s ETSI membership: ACT | The App(le) Association
ACT | The App(le) Association claims to be an ETSI member. It is not. Certainly not for months to come and not necessarily thereafter.
-
SEP holders push back against calls for withdrawal of withdrawal of EU SEP Regulation
The EU SEP Regulation is headed for its formal withdrawal, but there still is some wrangling behind the scenes that keeps lobbyists busy.
-
UPC’s Hamburg LD enters Unitary Patent PI: defendant bears burden on invalidity; new market opportunity is irreparable harm; security not automatic
A new decision by the UPC’s Hamburg LD lays out standards that create opportunities for other patentees seeking preliminary injunctions.
-
Patent-related complaints continue to dominate USITC Section 337 investigations
While the total number of Section 337 investigations dropped slightly in 2024, patent-related complaints continue to make up 88% of such ITC cases.
-
European Patent Office aligns with Unified Patent Court on claim construction standard: Enlarged Board of Appeal decision
Today’s decision by a Board of Appeal of the European Patent Office lays out a claim construction standard that is materially consistent with that of the Unified Patent Court’s Court of Appeal.
-
U.S. judge deprioritizes Samsung’s FRAND case against ZTE, UK judge requested post-hearing briefing on cross-jurisdictional implications
A federal judge in California has pushed back a hearing date by almost four months and a UK judge requested post-hearing briefing on Samsung’s multi-country FRAND lawsuits.
-
Federal Circuit decision in Optis v. Apple SEP case shows why UK courts should leave other jurisdictions alone: misconception exposed
In the seemingly neverending SEP story between Optis and Apple, the Federal Circuit has ordered a U.S. retrial on the merits and what would be a third damages trial in the same case.
-
Novartis and MSN settle part of chronic heart failure patent fight, but key patent remains
Novartis and MSN have settled one prong of their U.S. Entresto patent infringement dispute in the Federal Circuit, but the companies will continue to litigate over a second patent as Novartis strives to defend its corner of the chronic heart failure drug market.
-
Novo Nordisk lets key Ozempic patent lapse in Canada, despite being world’s second-largest semaglutide market
Novo Nordisk has continued to pay for a key Ozempic patent in several jurisdictions across the world, and even obtained an adjusted expiration date in the U.S., but the company stopped paying fees in Canada as far back as 2018, records show.
-
UPC Dusseldorf LD affirms 10x v. Curio preliminary injunction in final ruling, creates opening for late claim construction arguments
Having recently settled its dispute with Bruker (NanoString) on presumably favorable terms, 10x is now continuing its patent enforcement with a victory over Curio.